Heterogeneity in Tuberculosis

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2017 Jul 25

PMID 28736436

Citations 230

Authors

Anthony M Cadena

Sarah M Fortune

JoAnne L Flynn

Affiliations

Soon will be listed here.

Abstract

Infection with Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), results in a range of clinical presentations in humans. Most infections manifest as a clinically asymptomatic, contained state that is termed latent TB infection (LTBI); a smaller subset of infected individuals present with symptomatic, active TB. Within these two seemingly binary states, there is a spectrum of host outcomes that have varying symptoms, microbiologies, immune responses and pathologies. Recently, it has become apparent that there is diversity of infection even within a single individual. A good understanding of the heterogeneity that is intrinsic to TB - at both the population level and the individual level - is crucial to inform the development of intervention strategies that account for and target the unique, complex and independent nature of the local host-pathogen interactions that occur in this infection. In this Review, we draw on model systems and human data to discuss multiple facets of TB biology and their relationship to the overall heterogeneity observed in the human disease.

Citing Articles

Predicting tuberculosis drug efficacy in preclinical and clinical models from data.

Goh J, Patel A, Ngara B, Van Wijk R, Strydom N, Wang Q iScience. 2025; 28(3):111932.

PMID: 40034847 PMC: 11875147. DOI: 10.1016/j.isci.2025.111932.

The immunometabolic topography of tuberculosis granulomas governs cellular organization and bacterial control.

McCaffrey E, Delmastro A, Fitzhugh I, Ranek J, Douglas S, Peters J bioRxiv. 2025; .

PMID: 40027668 PMC: 11870603. DOI: 10.1101/2025.02.18.638923.

The importance of inflammatory biomarkers in detecting and managing latent tuberculosis infection.

Gunasekaran H, Ranganathan U, Bethunaickan R Front Immunol. 2025; 16:1538127.

PMID: 39981231 PMC: 11839662. DOI: 10.3389/fimmu.2025.1538127.

Cross-species transcriptomics translation reveals a role for the unfolded protein response in Mycobacterium tuberculosis infection.

Pullen K, Finethy R, Ko S, Reames C, Sassetti C, Lauffenburger D NPJ Syst Biol Appl. 2025; 11(1):19.

PMID: 39955299 PMC: 11830044. DOI: 10.1038/s41540-024-00487-6.

Systematic review of innate immune responses against complex infection in animal models.

Nieto Ramirez L, Mehaffy C, Dobos K Front Immunol. 2025; 15:1467016.

PMID: 39949719 PMC: 11821578. DOI: 10.3389/fimmu.2024.1467016.

References

Maini R, St Clair E, Breedveld F, Furst D, Kalden J, Weisman M . Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 2000; 354(9194):1932-9. DOI: 10.1016/s0140-6736(99)05246-0. View

Berry M, Graham C, McNab F, Xu Z, Bloch S, Oni T . An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010; 466(7309):973-7. PMC: 3492754. DOI: 10.1038/nature09247. View

Chengalroyen M, Beukes G, Gordhan B, Streicher E, Churchyard G, Hafner R . Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis. Am J Respir Crit Care Med. 2016; 194(12):1532-1540. PMC: 5215032. DOI: 10.1164/rccm.201604-0769OC. View

Orme I, Robinson R, Cooper A . The balance between protective and pathogenic immune responses in the TB-infected lung. Nat Immunol. 2014; 16(1):57-63. DOI: 10.1038/ni.3048. View

Behar S, Carpenter S, Booty M, Barber D, Jayaraman P . Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus. Semin Immunol. 2014; 26(6):559-77. PMC: 4250436. DOI: 10.1016/j.smim.2014.09.003. View

Getahun H, Matteelli A, Chaisson R, Raviglione M . Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015; 372(22):2127-35. DOI: 10.1056/NEJMra1405427. View

Lieberman T, Wilson D, Misra R, Xiong L, Moodley P, Cohen T . Genomic diversity in autopsy samples reveals within-host dissemination of HIV-associated Mycobacterium tuberculosis. Nat Med. 2016; 22(12):1470-1474. PMC: 5508070. DOI: 10.1038/nm.4205. View

Coleman M, Maiello P, Tomko J, Frye L, Fillmore D, Janssen C . Early Changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun. 2014; 82(6):2400-4. PMC: 4019174. DOI: 10.1128/IAI.01599-13. View

Lerner T, Borel S, Gutierrez M . The innate immune response in human tuberculosis. Cell Microbiol. 2015; 17(9):1277-85. PMC: 4832344. DOI: 10.1111/cmi.12480. View

10.

Young D, Gideon H, Wilkinson R . Eliminating latent tuberculosis. Trends Microbiol. 2009; 17(5):183-8. DOI: 10.1016/j.tim.2009.02.005. View

11.

Chen R, Dodd L, Lee M, Paripati P, Hammoud D, Mountz J . PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med. 2014; 6(265):265ra166. PMC: 5567784. DOI: 10.1126/scitranslmed.3009501. View

12.

Malherbe S, Shenai S, Ronacher K, Loxton A, Dolganov G, Kriel M . Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med. 2016; 22(10):1094-1100. PMC: 5053881. DOI: 10.1038/nm.4177. View

13.

Cilfone N, Perry C, Kirschner D, Linderman J . Multi-scale modeling predicts a balance of tumor necrosis factor-α and interleukin-10 controls the granuloma environment during Mycobacterium tuberculosis infection. PLoS One. 2013; 8(7):e68680. PMC: 3711807. DOI: 10.1371/journal.pone.0068680. View

14.

Joseph S, Swanstrom R, Kashuba A, Cohen M . Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat Rev Microbiol. 2015; 13(7):414-25. PMC: 4793885. DOI: 10.1038/nrmicro3471. View

15.

Zumla A, Nahid P, Cole S . Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013; 12(5):388-404. DOI: 10.1038/nrd4001. View

16.

Flynn J, Gideon H, Mattila J, Lin P . Immunology studies in non-human primate models of tuberculosis. Immunol Rev. 2015; 264(1):60-73. PMC: 4339213. DOI: 10.1111/imr.12258. View

17.

Cooper A, Mayer-Barber K, Sher A . Role of innate cytokines in mycobacterial infection. Mucosal Immunol. 2011; 4(3):252-60. PMC: 3294290. DOI: 10.1038/mi.2011.13. View

18.

Walker T, Ip C, Harrell R, Evans J, Kapatai G, Dedicoat M . Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis. 2012; 13(2):137-46. PMC: 3556524. DOI: 10.1016/S1473-3099(12)70277-3. View

19.

Lin P, Flynn J . Understanding latent tuberculosis: a moving target. J Immunol. 2010; 185(1):15-22. PMC: 3311959. DOI: 10.4049/jimmunol.0903856. View

20.

Subbian S, Tsenova L, Kim M, Wainwright H, Visser A, Bandyopadhyay N . Lesion-Specific Immune Response in Granulomas of Patients with Pulmonary Tuberculosis: A Pilot Study. PLoS One. 2015; 10(7):e0132249. PMC: 4489805. DOI: 10.1371/journal.pone.0132249. View